No Detail Found!

Hepatitis d treatment with pegylated interferon: outcome asking for an urgent alternative

Author(s)
Abdul Rabb Bhutto Department of Medicine, Al-Tibri Medical College Hospital Isra University Karachi Campus, Pakistan
Amanullah Abbasi Medical Unit II, Department of Medicine, Dow University Hospital, Dow University of Health Science Karachi, Pakistan
Shumaila Rafi Department of Institute of Health Professional Education, Dow University of Health Sciences, Karachi, Pakistan
Khalil ur Rehman Department of Medicine, Sir Syed Medical College,Karachi, Pakistan
Syed Tehseen Akhtar Department of Medicine, Medical Unit II, Civil Hospital Dow University of Health Sciences,Karachi, Pakistan
Muhammad Hussain Haroon Department of Medicine, Dow University of Health Sciences,Karachi, Pakistan
Abstract
BACKGROUND: Viral hepatitis is a global health issue mainly prevalent in countries in Asia and Africa where hepatitis B (HBV) is endemic. OBJECTIVE: To determine the efficacy of pegylated interferon alpha in Hepatitis D patients. STUDY DESIGN: Quasi-experimental study. PLACE AND DURATION OF STUDY: Al-Tibri Medical College Hospital Karachi and OPD Saylani Welfare Trust Karachi from August 2021 to December 2022. METHODOLOGY: Adult patients of either gender and all ages infected with HDV as evidenced by anti-HDV antibodies positive along with detectable levels of HDV RNA in the serum by polymerase chain reaction (PCR) were included in the study. A written informed consent was taken from all patients, and pegylated interferon alpha (180 mcg subcutaneously weekly) was started for at 48 weeks. HDV RNA by quantitative PCR has been done before and after treatment. All patients were followed up in the outpatient clinics every month for clinical, hematological, and biochemical assessments for any adverse effects of treatment. At the end of treatment, the overall response to therapy as depicted by non-detectable HDV RNA by PCR was analyzed by applying the chi-square test and using SPSS 23.0 statistical software. Significance was kept at a p-value of less than 0.05. RESULTS: Ninety-seven patients were assessed for eligibility. After excluding 31 patients, a total of 66 patients were enrolled for a 48-week course of pegylated interferon therapy at a dose of 180 mg/week. Out of the 42 patients, 16 (38.1%) responded to the treatment, compared to 26 (61.9%) no responders. No significant difference was seen in association with gender, age and viral load of patients with responders and non-responder's groups of treatment. CONCLUSION: The study found that pegylated interferon treatment of hepatitis D patients was challenging, with only 38% of patients achieving sustained suppression of hepatitis D virus replication after 48 weeks of treatment.
Publication Details
Page(s) 106-112
Published Journal: journal of Peoples University of medical and Health Sciences, Pakistan., Volume: 13, Issue: 2, Year: 2023

Request the full text from PASTIC

Keywords
Hepatitis D. Pegylated interferon alpha. Polymerase Chain Reaction
0

Citations

0

Downloads

52

Views